David Hutton

According to a news release, the Redwood City, California, site will complement Eyenovia’s facility in Reno, Nevada as well as its contract manufacturer, Coastline International, to produce commercial supply of Mydcombi.

David Hutton of Ophthalmology Times talks with Brian Strem, PhD, CEO Kiora Pharmaceuticals, about their recent partnership with Théa Open Innovation and further development of their KIO-301 and KOI-104 programs.

According to the organization, GYROS results will help researchers design clinical trials for an emerging gyrate atrophy gene therapy.

Amani Fawzi, MD, is inducted into the society. Her research uses translational approaches to study age-related macular degeneration and diabetic retinopathy.

Rey Pena is known as Eye of the Niner because of the team logo he had printed onto the prosthetic eye he wears in honor of the team.

Researchers noted a study by Ruhr-University Bochum researchers provides crucial evidence that the ECM influences visual sensory motor behavior already at the retina level, without intervention of disease and/or experimental manipulation.

Joseph Panarelli, MD, sat down with David Hutton of Ophthalmology Times to discuss the panel he moderated at the Glaucoma 360 meeting held in San Francisco, about innovations in glaucoma drugs, and drug delivery.

Adrienne Graves, PhD, and Andrew Iwach, MD, co-founders of Glaucoma 360, highlight the 13th annual Glaucoma 360 New Horizons Forum, held this year at the Westin St. Francis San Francisco on Union Square.

Tonian McDonald shares her story during the Glaucoma 360 New Horizons Forum at the Westin St. Francis Hotel in San Francisco to recount her journey as a glaucoma patient.

OK-101 is the first IND clearance granted by the FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain.

Hoskins was a pioneer and leader in the field of ophthalmology and glaucoma, and served as executive vice president of the American Academy of Ophthalmology, founding director and Director Emeritus of the Glaucoma Research Foundation, and a founding director of the American Glaucoma Society.

According to the company, AGTC-501 was generally safe and well-tolerated and showed improvements in visual function at the 12-month analysis. The Phase 2/3 VISTA trial for AGTC-501 in XLRP expected to begin in in the first half of 2024.

Preliminary safety data support a favorable benefit-risk profile at both dose levels. The preliminary efficacy and safety data trending similar to or better than the OPTIC study, in which patients continue to see ongoing clinical benefit through at least 3 years.

AAO president will deliver the annual Tullos O. Coston, MD lectureship on June 1, 2024.

Clearside noted in a news release it intends to use the net proceeds from this offering for working capital and general corporate purposes.

The patent further protects Iridex’s intellectual property encompassing laser systems in ophthalmology and related fields.

A team of neuroscientists at Johns Hopkins show how specialized cells signal the presence of light simultaneously in two distinct ways.

Toku’s AI technology, CLAiR, has obtained CE and UKCA Marks. CLAiR provides fast, accurate, non-invasive cardiovascular disease (CVD) risk assessments using standard retinal images.

According to the company, 4D-150 was well tolerated with a favorable safety profile when evaluated through up to 48 weeks of follow-up, with no significant inflammation observed.

Massachusetts Eye and Ear researchers came up with a mobile app called All_Aboard, designed to be used along with mainstream GPS systems and focuses on improving micro-navigation.

SriniVas R. Sadda, MD, sat down with David Hutton of Ophthalmology Times to discuss his presentation about precursor lesions for development of atrophy and AMD from the Angiogenesis Exudation and Degeneration 2024 event.

Trial will analyze efficacy, safety of AVD-104 versus avacincaptad pegol to treat GA

Under the terms of the agreement, Kiora Pharmaceuticals and Théa Open Innovation will develop and commercialize KIO-301 for the treatment of inherited retinal diseases in a deal valued at up to $301 million.

The agreement settles Zeiss’s lawsuit against Topcon’s U.S.-based subsidiaries that had been set to start this month in U.S. federal court for the Northern District of California.

In a news release, the FDA noted these are copycat eye drop products that consumers can easily mistake for Bausch + Lomb’s Lumify brand eye drops, an over-the-counter product approved for redness relief.

According to the company, the deals from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, and Degeneration 2024.

A University of Houston professor found that the excitement over the results of LLR as a treatment option for patients with myopia may have come too soon, before its efficacy was confirmed. One company is taking exception with the study.

Wilmer's expansive focus and deep bench are advancing the understanding of artificial intelligence tools and potential ophthalmic applications.

The licensing deal includes upfront, development milestones, and sales royalties, with additional considerations throughout the term of the agreement.

Sanders is affiliated with the Retina Group of Washington (RGW) and PRISM Vision Group. He is the first African American and the first PRISM-affiliated physician to serve as president of the ASRS.